ID   OVCAR-2
AC   CVCL_3941
SY   NIH:OVCAR-2; OVCAR2; OVCAR 2
DR   BTO; BTO_0002560
DR   cancercelllines; CVCL_3941
DR   GEO; GSM185133
DR   GEO; GSM185134
DR   GEO; GSM711707
DR   GEO; GSM851933
DR   GEO; GSM1340586
DR   GEO; GSM1341131
DR   Progenetix; CVCL_3941
DR   Wikidata; Q54937004
RX   PubMed=1348364;
RX   PubMed=2307530;
RX   PubMed=3930572;
RX   PubMed=6372095;
RX   PubMed=6385258;
RX   PubMed=9041185;
RX   PubMed=22710073;
CC   Problematic cell line: Partially contaminated. Some stocks were contaminated by either Calu-6 or Caov-2 as identified by a STR profile (PubMed=22710073).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Miscellaneous: STR profile from personal communication of Campbell, Kerry S. at Fox Chase Cancer Center. The stocks of OVCAR-2 used for profiling were obtained in 1982 from Hamilton, Thomas C. lab, where OVCAR-2 was established.
CC   Caution: The STR profile reported by PubMed=22710073 was Amelogenin: X; CSF1PO: 12; D13S317: 11; D16S539: 13; D18S51: 12,16; D19S433: 13; D21S11: 31; D2S1338: 17,26; D3S1358: 16; D5S818: 11; D7S820: 10; D8S1179: 10,14; FGA: 22; TH01: 9; TPOX: 8; vWA: 17.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 13
ST   D18S51: 12
ST   D21S11: 30,32.2
ST   D3S1358: 14,15
ST   D5S818: 11,13
ST   D7S820: 8,12
ST   D8S1179: 9,14
ST   FGA: 20
ST   Penta D: 8,9,13
ST   Penta E: 13
ST   TH01: 8,9
ST   TPOX: 11
ST   vWA: 17,18
DI   NCIt; C4908; Ovarian carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 27-11-25; Version: 20
//
RX   PubMed=3930572; DOI=10.1172/JCI112082; PMCID=PMC424036;
RA   Pirker, Robert
RA   FitzGerald, David J.P.
RA   Hamilton, Thomas C.
RA   Ozols, Robert F.
RA   Laird, Walter Joseph
RA   Frankel, Arthur Edward
RA   Willingham, Mark C.
RA   Pastan, Ira
RT   "Characterization of immunotoxins active against ovarian cancer cell
RT   lines.";
RL   J. Clin. Invest. 76:1261-1267(1985).
//
RX   PubMed=9041185;
RA   Johnson, Steven W.
RA   Laub, Paul B.
RA   Beesley, Jacqueline S.
RA   Ozols, Robert F.
RA   Hamilton, Thomas C.
RT   "Increased platinum-DNA damage tolerance is associated with cisplatin
RT   resistance and cross-resistance to various chemotherapeutic agents in
RT   unrelated human ovarian cancer cell lines.";
RL   Cancer Res. 57:850-856(1997).
//
RX   PubMed=6372095; DOI=10.1126/science.6372095;
RA   Rogan, Alfred M.
RA   Hamilton, Thomas C.
RA   Young, Robert C.
RA   Klecker, Raymond W. Jr.
RA   Ozols, Robert F.
RT   "Reversal of adriamycin resistance by verapamil in human ovarian
RT   cancer.";
RL   Science 224:994-996(1984).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677;
RA   Korch, Christopher T.
RA   Spillman, Monique Ann
RA   Jackson, Twila A.
RA   Jacobsen, Britta M.
RA   Murphy, Susan K.
RA   Lessey, Bruce Arthur
RA   Jordan, Virgil Craig
RA   Bradford, Andrew Peter
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=2307530; DOI=10.1002/ijc.2910450306;
RA   Schilder, Russell J.
RA   Hall, Lemuel
RA   Monks, Anne
RA   Handel, Laura M.
RA   Fornace, Albert J. Jr.
RA   Ozols, Robert F.
RA   Fojo, Antonio
RA   Hamilton, Thomas C.
RT   "Metallothionein gene expression and resistance to cisplatin in human
RT   ovarian cancer.";
RL   Int. J. Cancer 45:416-422(1990).
//
RX   PubMed=1348364; DOI=10.1073/pnas.89.7.3070; PMCID=PMC48805;
RA   Godwin, Andrew Kent
RA   Meister, Alton
RA   O'Dwyer, Peter J.
RA   Huang, Chin-Shiou
RA   Hamilton, Thomas C.
RA   Anderson, Mary E.
RT   "High resistance to cisplatin in human ovarian cancer cell lines is
RT   associated with marked increase of glutathione synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992).
//
RX   PubMed=6385258;
RA   Hamilton, Thomas C.
RA   Young, Robert C.
RA   Ozols, Robert F.
RT   "Experimental model systems of ovarian cancer: applications to the
RT   design and evaluation of new treatment approaches.";
RL   Semin. Oncol. 11:285-298(1984).
//